11-NOV-2024 Actual company guidance: 2024: 415 MUSD revenue (S24) and net income 120 MUSD (E24), 2025: 465 MUSD (S25), 165 MUSD net income (E25) Market cap of 5.35 BUSD (P) at 22.62/share: P/S24 = 12.9, P/E24 = 44.6, P/S25 = 11.5 and P/E25 = 32.4) My assumptions: ADMA will be highly profitable due to high ratio of hyperimmunes (maybe eventually they will only manufacture hyperimmunes if S. pneumonia is successful and provided they can source the required amount of hyperimmune plasma).Read more
A growing need for immune treatments and a push to collect and process more plasma could help ADMA Biologics sell more of its key therapy and improve profitability faster than many expect. But the story hinges on a small number of products and a tight supply chain, and changes in reimbursement, regulation, or new competing treatments could quickly reshape the outlook.Read more
Key Takeaways Adoption of manufacturing improvements, capacity expansions, and new products is driving margin growth, revenue diversification, and improved supply chain resilience. Enhanced liquidity from refinancing and strong market demand underpins strategic growth initiatives and positions the company for sustained earnings improvement.Read more
Key Takeaways Heavy reliance on plasma-derived products and a concentrated portfolio exposes the company to emerging therapies, regulatory risks, and market volatility. Increasing competition, regulatory scrutiny, and rising operational expenses may restrict market share growth, compress margins, and hinder long-term financial performance.Read more
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
